Combining Metacognitive Training with Cognitive Remediation for Psychotic Disorders
Benefits of Combining Metacognitive Training (MCT) With Cognitive Remediation (CR) in the Recovery of Patients With Psychotic Spectrum Disorders (CR+MCTp)
This study is testing whether combining two types of therapy can help people with nonaffective psychotic disorders recover better than just using one type of therapy alone.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 160 (estimated) |
| Ages | 16 Years to 55 Years |
| Sex | All |
| Sponsor | Universitat Autonoma de Barcelona Academic / other |
| Locations | 1 site (Cerdanyola del Vallès, Barcelona) |
| Trial ID | NCT06423651 on ClinicalTrials.gov |
What this trial studies
This clinical trial aims to evaluate the effectiveness of combining REHACOP (Cognitive Remediation) with Metacognitive Training (MCT) in improving recovery outcomes for individuals with nonaffective psychotic disorders. Participants will be assigned to either the combined therapy or MCT alone, and their progress will be assessed in terms of clinical recovery, personal recovery, cognitive biases, and social cognition. The study also seeks to understand the long-term effects of these interventions and how gender differences may influence outcomes.
Who should consider this trial
Good fit: Ideal candidates include individuals diagnosed with schizophrenia or related disorders who are stable and compliant with their pharmacological treatment.
Not a fit: Patients with severe cognitive impairments or those exhibiting high levels of hostility and suspicion may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could significantly enhance recovery and quality of life for patients with psychotic disorders.
How similar studies have performed: Previous studies have shown promise in using cognitive interventions for psychotic disorders, suggesting potential success for this combined approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Presence of one of the e following diagnostics according to the criteria of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5): schizophrenia, schizophreniform disorder, delusional disorder, brief psychotic disorder, schizoaffective disorder, and non specified schizophrenia spectrum disorder and other psychotic disorders. * Be in a stable clinical phase (without psychiatric hospitalization in the last 3 months). * Have good adherence to pharmacological treatment. * T-score \< 40 in any cognitive outcome measured by TAVEC, CPT-IP, TMT, Stroop, WSCT, FAS and WAIS (Vocabulary, Digit Forward, Digit Backwards and Digit Symbol Coding. * Willing to participate in the study expressed by providing signed informed consent. Exclusion Criteria: * Presence of traumatic brain lesion, dementia or intellectual discapacity (IQ \<70). * Positive and Negative Syndrome Scale (PANSS) score \>= 5 in hostility and lack of cooperation and \>= 6 in suspiciousness. * Presence of an additional diagnosis of severe disorder related to substances. * Having participated in a CR and/or MCT intervention in the year prior to incorporation into the study.
Where this trial is running
Cerdanyola del Vallès, Barcelona
- Universitat Autonoma de Barcelona — Cerdanyola del Vallès, Barcelona, Spain (Recruiting)
Study contacts
- Principal investigator: Ana Barajas Velez — Universitat Autonoma de Barcelona
- Study coordinator: Ana Barajas Velez
- Email: ana.barajas@uab.cat
- Phone: +34935814452
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.